Methodological criticisms in the evaluation of pneumococcal conjugate vaccine effectiveness

C. Trucchi, C. Paganino, F. Ansaldi

Research output: Contribution to journalArticlepeer-review


Globally, lower respiratory tract infections (LRTIs), including community-acquired pneumonia (CAP), cause considerable of morbidity and mortality in adults, especially in the elderly. In addition to age, underlying medical conditions are associated with an increased risk of CAP. From an aetiological point of view, Streptococcus pneumoniae is the leading cause of adult CAP throughout the world. Two types of vaccine are available for the prevention of pneumococcal diseases: the pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal conjugate vaccine (PCV7, PCV10 and PCV13). An accurate understanding of the LRTIs burden and the types of subjects at risk of CAP, allow to find an appropriately targeted immunization strategy and provide baseline data to evaluate pneumococcal vaccine effectiveness. Given the high variability in available estimates of LRTIs burden and associated risk factors, the objective of the study was to discuss the methodological criticism in its evaluation, in the light of the gradual introduction of PCV13 immunization strategy targeted to elderly and risk groups in middle-high income countries.

Original languageEnglish
Pages (from-to)E144-E149
JournalJournal of Preventive Medicine and Hygiene
Issue number3
Publication statusPublished - Sep 1 2015


  • Conjugate vaccine
  • Effectiveness
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Methodological criticisms in the evaluation of pneumococcal conjugate vaccine effectiveness'. Together they form a unique fingerprint.

Cite this